Fundsmith Reduces $207M in Stryker Corporation ($SYK)
Key Points
- Fundsmith changed its Stryker Corporation ($SYK) stake by 16.98% last quarter, cutting to 3,061,416 shares worth $1.01 billion.
- Wall Street's consensus rating on $SYK is Buy and an average price target of $382.72.
- $SYK last traded around $330.52.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Fundsmith reduced its position in Stryker Corporation ($SYK) by 16.98% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,061,416 shares of Stryker Corporation after selling 626,095 shares during the quarter. Fundsmith's holdings in Stryker Corporation were worth $1.01 billion as of its most recent filing.
Stryker Corporation Stock Down 0.1%
Shares of Stryker Corporation ($SYK) traded around $330.52 on Saturday, down 0.1% for the day.
Stryker Corporation Earnings
Stryker Corporation Dividend
Analysts Set New Price Targets
About Stryker Corporation
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Get Stryker Corporation alerts
New 13F filings, insider trades, and analyst moves on $SYK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.